Combination therapy for treating obesity or maintaining weight loss
First Claim
1. A method for treating obesity and related eating disorders comprising the step of administering a therapeutically effective amount of a combination comprising a cannabinoid-1 receptor antagonist and an intestinal-acting microsomal triglyceride transfer protein inhibitor to an animal in need of such treatment.
0 Assignments
0 Petitions
Accused Products
Abstract
Combination therapies for treating obesity or related eating disorders and/or reducing food consumption are described herein which comprises administering a therapeutically effective amount of a cannabinoid-1 (CB-1) receptor antagonist and an intestinal-acting microsomal triglyceride transfer protein inhibitor (MTPi) to an animal in need of such treatment. The CB-1 receptor antagonist and intestinal-acting MTPi may be administered separately or together.
-
Citations
9 Claims
- 1. A method for treating obesity and related eating disorders comprising the step of administering a therapeutically effective amount of a combination comprising a cannabinoid-1 receptor antagonist and an intestinal-acting microsomal triglyceride transfer protein inhibitor to an animal in need of such treatment.
-
2. A method for reducing food consumption comprising comprising the step of administering a therapeutically effective amount of a combination comprising a cannabinoid-1 receptor antagonist and an intestinal-acting microsomal triglyceride transfer protein inhibitor to an animal in need of such treatment.
-
9. A pharmaceutical composition (i) a CB-1 receptor antagonist;
- (ii) a intestinal-acting MTPi; and
(iii) a pharmaceutically acceptable excipient, diluent, or carrier, wherein the amount of CB-1 receptor antagonist is from about 1.0 mg to about 100 mg and the amount of intestinal-acting MTPi is from about 0.05 mg to about 50 mg.
- (ii) a intestinal-acting MTPi; and
Specification